Meenhard Herlyn

Has grant

Professor, Director

The Wistar Institute
Country flagUnited States
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Close

Targeting Aldehyde Dehydrogenase for Cancer Prevention

Open Date: 2020-04-15

Close Date: 2025-03-31

Grant: Close

Understanding and Overcoming Resistance to BRAF/MEK Kinase Inhibitors in Melanoma

Open Date: 2019-12-13

Close Date: 2024-11-30

Grant: Close

Overcoming Resistance to Signaling and Immune

Open Date: 2019-10-01

Close Date: 2022-09-01

Grant: Close

Rational approaches to melanoma therapy

Open Date: 2017-09-30

Close Date: 2022-08-31

Grant: Close

SPORE in Skin Cancer

Open Date: 2014-09-16

Close Date: 2021-08-31

Articles (19)

Supplemental Table S1: Patient Characteristics by UGCG expression defined Risk Groups in the Learning Dataset; Supplemental Table S2: Patient Characteristics by UGCG expression defined Risk Groups in the Validation Dataset (Cirenajwis et al., 2015)

Year:

2025

Supplemental Figure S1: LAI remodels the lipidome of melanoma cells. Supplemental Figure S2: LAI induces UGCG, and UGCG inhibition augments DC661 cytotoxicity, and this effect is not seen by blocking cholesterol synthesis and key earlier steps of autophagy. Supplemental Figure S3: LAI increases the formation of GMM in cancer cells. Supplemental Figure S4: UGCG inhibition synergistically augments LAI induced cytotoxicity and abrogates GMM formation without elevating ceramide levels. Supplemental Figure S5: LAI induces UGCG-associated GMM formation in PDX cells, a combination of DC661 and eliglustat impairs tumor growth in a therapy-resistant PDX tumor model.

Year:

2025

Most advanced melanomas initially respond to targeted therapy but eventually relapse. Rather than acquiring new mutations, resistance is driven by drug-tolerant persister cells that enter a reversible drug-refractory state. We developed MeRLin, a high-resolution lineage tracing platform integrating cellular barcoding, single-cell transcriptomics, RNA fluorescence in situ hybridization (FISH), and computational analyses to track clonal and transcriptional dynamics in patient-derived melanoma models during prolonged therapy. Clonal dynamics revealed that persister subpopulations first responded to treatment but persisted and expanded during minimal residual disease, ultimately leading to tumor recurrence. Pre-treatment melanoma populations diversified into four conserved persister states characterized by stress-like, lipid metabolism, PI3K signaling, and extracellular matrix remodeling programs associated with adaptive resistance. Spatial transcriptomics showed the organization of these adaptive programs and a complex signaling network of autocrine and paracrine interactions among persister subpopulations. Barcoded RNA-FISH enabled spatial mapping of clonal identity and gene expression, revealing in situ co-localization of a dominant resistant clone with SLC2A1 expression. MeRLin provides a robust framework for dissecting cancer heterogeneity and identifying vulnerabilities in persister populations.

Year:

2025

Acral melanoma (AM) is an aggressive melanoma subtype with limited therapeutic options and poor outcomes. In non-European descent and admixed populations, like those residing in Latin America, AM accounts for a significant proportion of cutaneous melanoma cases. Here, we performed comprehensive genomic and functional profiling of AM from a uniquely diverse Brazilian cohort. Whole-exome and transcriptome sequencing revealed low mutation burden and predominance of copy number alterations, including high-amplitude focal amplifications termed hailstorms. These hailstorms frequently affected chromosomes 11, 5 and 22 and key oncogenes such as CCND1 , GAB2 , CDK4 , and TERT . The presence of hailstorms in the long arms of chromosomes 11 and 22 was associated with higher focal copy number burden and loss of DNA damage response genes ( ATM , CHEK1 ), suggesting a permissive genomic environment driving structural instability. To explore the unique genomic context of AM, we established a comprehensive collection of patient-derived xenograft (AM-PDX) models that faithfully retain the histopathological and genomic features of the original tumours. Functional exploration of AM-specific vulnerabilities through pharmacological and CRISPR/Cas9 knockout screenings identified strong sensitivity to targeting MAPK, CDK4/6, MDM2, and WEE1 pathways. Notably, the pan-RAS(ON) inhibitor RMC-7977 effectively reduced viability in NRAS -, KRAS -, and KIT -mutant AM cell lines. Finally, CRISPR screens revealed dependencies selectively essential in AM, including CRKL and SF3B4 , highlighting previously unrecognized vulnerabilities. Our findings emphasize the distinct biology of AM compared to other subtypes of melanoma, provide a valuable resource of models reflective of Latin American ancestry, and identify potential drivers and therapeutic targets.

Year:

2025

Resistance of BRAF -mutant melanomas to targeted therapy arises from the ability of cells to enter a persister state, evade treatment with relative dormancy, and repopulate the tumor when reactivated. A better understanding of the temporal dynamics and specific pathways leading into and out of the persister state is needed to identify strategies to prevent treatment failure. Using spatial transcriptomics in patient-derived xenograft models, we captured clonal lineage evolution during treatment. The persister state showed increased oxidative phosphorylation, decreased proliferation, and increased invasive capacity, with central-to-peripheral gradients. Phylogenetic tracing identified intrinsic and acquired resistance mechanisms (e.g., dual-specific phosphatases, reticulon-4, and cyclin-dependent kinase 2) and suggested specific temporal windows of potential therapeutic susceptibility. Deep learning–enabled analysis of histopathologic slides revealed morphologic features correlating with specific cell states, demonstrating that juxtaposition of transcriptomics and histologic data enabled identification of phenotypically distinct populations from using imaging data alone. In summary, this study defined state change and lineage selection during melanoma treatment with spatiotemporal resolution, elucidating how choice and timing of therapeutic agents will impact the ability to eradicate resistant clones. Significance: Tracking clonal progression during treatment uncovers conserved, global transcriptional changes and local clone–clone and spatial patterns underlying the emergence of resistance, providing insights into therapy-induced tumor evolution.

Year:

2025

Differentially expressed genes between time point 1 and time point 0 with significant corrected p-values in the resistant lineages (1, 2) but not in the sensitive lineages (0, 5, 8) , in the sensitive but not resistant, and in both sensitive and resistant (WM4007).

Year:

2025

Chimeric antigen receptor (CAR) T-cell therapy has shown remarkable success in the treatment of hematologic malignancies. Unfortunately, it has limited efficacy against solid tumors, even when the targeted antigens are well expressed. A better understanding of the underlying mechanisms of CAR T-cell therapy resistance in solid tumors is necessary to develop strategies to improve efficacy. Here we report that solid tumors release small extracellular vesicles (sEV) that carry both targeted tumor antigens and the immune checkpoint protein PD-L1. These sEVs acted as cell-free functional units to preferentially interact with cognate CAR T cells and efficiently inhibited their proliferation, migration, and function. In syngeneic mouse tumor models, blocking tumor sEV secretion not only boosted the infiltration and antitumor activity of CAR T cells but also improved endogenous antitumor immunity. These results suggest that solid tumors use sEVs as an active defense mechanism to resist CAR T cells and implicate tumor sEVs as a potential therapeutic target to optimize CAR T-cell therapy against solid tumors. Significance: Small extracellular vesicles secreted by solid tumors inhibit CAR T cells, which provide a molecular explanation for CAR T-cell resistance and suggests that strategies targeting exosome secretion may enhance CAR T-cell efficacy. See related commentary by Ortiz-Espinosa and Srivastava, p. 2637

Year:

2025

Drug tolerance and minimal residual disease (MRD) are likely to prelude acquired resistance to targeted therapy. Mechanisms that allow persister cells to survive in the presence of targeted therapy are being characterized but selective vulnerabilities for these subpopulations remain uncertain. We identified cellular inhibitor of apoptosis protein 2 (cIAP2) as being highly expressed in SOX10-deficient drug tolerant persister (DTP) melanoma cells. Here, we show that cIAP2 is sufficient to induce tolerance to MEK inhibitors, likely by decreasing the levels of cell death. Mechanistically, cIAP2 is upregulated at the transcript level in SOX10-deficient cells and the AP-1 complex protein, JUND, is required for its expression. Using a patient-derived xenograft model, we demonstrate that treatment with the cIAP1/2 inhibitor, birinapant, during the MRD phase delays the onset of resistance to BRAF inhibitor and MEK inhibitor combination therapy. Together, our data suggest that cIAP2 upregulation in SOX10-deficient subpopulations of melanoma cells induces drug tolerance to MAPK targeting agents and provides a rationale to test a novel therapeutical approach to target MRD.

Year:

2025

Melanoma is a common and aggressive cancer, with a rising incidence in most developed countries. Major discoveries in melanoma biology have been rapidly translated, allowing cures for some late-stage patients. Despite these advances, incomplete knowledge of genes and pathways that are gained or lost during melanogenesis prohibits cures for many patients. To identify gain-of-function and loss-of-function drivers of melanoma, we established a multi-omics cohort of melanoma patient-derived xenografts. By linking mutations with gene and protein expression, we characterize gain or loss-of-function of specific melanoma drivers in treatment refractory tumor models. We use multi-omics integration and structural-context representation to distinguish gain from loss of function variants, revealing new candidate melanoma genes and targets. This study provides a comprehensive resource of tumor models with the genetic, molecular and structural features of gain and loss of function melanoma drivers, allowing future development of better therapeutics for this devastating and heterogenous malignancy.

Year:

2024

Chimeric antigen receptor (CAR) T cell therapy has shown remarkable success in the treatment of hematologic malignancies. Unfortunately, it has limited efficacy against solid tumors, even when the targeted antigens are well expressed. A better understanding of the underlying mechanisms of CAR T cell therapy resistance in solid tumors is necessary to develop strategies to improve efficacy. Here we report that solid tumors release small extracellular vesicles (sEVs) that carry both targeted tumor antigens and the immune checkpoint protein PD-L1. These sEVs acted as cell-free functional units to preferentially interact with cognate CAR T cells and efficiently inhibited their proliferation, migration, and function. In syngeneic mouse tumor models, blocking tumor sEV secretion not only boosted the infiltration and anti-tumor activity of CAR T cells but also improved endogenous anti-tumor immunity. These results suggest that solid tumors use sEVs as an active defense mechanism to resist CAR T cells and implicate tumor sEVs as a potential therapeutic target to optimize CAR T cell therapy against solid tumors.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (54)

Lawrence Rubinstein

Statistician

National Cancer Institute

UNITED STATES
View details

Matthew H Bailey

Assistant Professor

Brigham Young University

UNITED STATES
View details

Jose G. Trevino

Virginia Commonwealth University

UNITED STATES
View details

Gordon Mills

Professor

Oregon Health & Science University

UNITED STATES
View details

Michael A. Davies

-

UNITED STATES
View details

Zebin Xiao

Professor

University of Pennsylvania

UNITED STATES
View details

Sherri Davies

Senior Scientist

Washington University in St. Louis

UNITED STATES
View details

Min Jin Ha

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Lisa McShane

Associate Director, Division of Cancer Treatment & Diagnosis

National Cancer Institute

UNITED STATES
View details

Monika Bhardwaj

Assistant Professor-II

Amity University Noida

View details

Carl H. June

Professor

University of Pennsylvania

UNITED STATES
View details

Peter Robinson

Professor for Medical Computer Science

The Jackson Laboratory for Genomic Medicine

UNITED STATES
View details

Jeffrey Chuang

Jackson Laboratory

UNITED STATES
View details

Xiaowei Xu

Professor

University of Pennsylvania

UNITED STATES
View details

Shidan Wang

-

UNITED STATES
View details

Serge Y. Fuchs

University of Pennsylvania

UNITED STATES
View details

Junya Fujimoto

Professor and Chair

Hiroshima University Hospital

JAPAN
View details

Inna Chervoneva

Thomas Jefferson University

UNITED STATES
View details

Neil C. Sheppard

PI

University of Pennsylvania

UNITED STATES
View details

Alana Welm

Chair

Huntsman Cancer Institute

UNITED STATES
View details

Nicholas Mitsiades

Professor

University of California, Davis

UNITED STATES
View details

Bryan Welm

Associate Professor

Huntsman Cancer Institute

UNITED STATES
View details

Xuelin Huang

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Shunqiang Li

Associate Professor

Washington University in St. Louis

UNITED STATES
View details

Jessie Villanueva

Associate Professor

The Wistar Institute

UNITED STATES
View details

Jennifer A. Wargo

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Jing Wang

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Ryan C. Fields

University of Rochester

UNITED STATES
View details

Tara C. Mitchell

-

UNITED STATES
View details

David Adams

Senior Group Leader (and Interim Programme Head)

Wellcome Sanger Institute

UNITED KINGDOM
View details

Luis G Carvajal‐Carmona

Professor

University of California, Davis

UNITED STATES
View details

David W Speicher

Professor

The Wistar Institute

UNITED STATES
View details

Funda Meric-Bernstam

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Robert Mashl

Washington University in St. Louis

UNITED STATES
View details

Chong-xian Pan

Professor

university of california davis medical center

UNITED STATES
View details

Carol Bult

Professor and Knowlton Family Chair

Jackson Laboratory

UNITED STATES
View details

Salma Kaochar

Assistant Professor

Baylor College of Medicine

UNITED STATES
View details

Li Ding

Associate Professor

Washington University in Saint Louis School of Medicine

UNITED STATES
View details

Carla Daniela Robles-Espinoza

Group Leader

National Autonomous University of Mexico

View details

J. Chuck Harrell

Virginia Commonwealth University

UNITED STATES
View details

Noam Auslander

Assistant professor

The Wistar Institute

UNITED STATES
View details

Andrew E. Aplin

Thomas Jefferson University

UNITED STATES
View details

Wei Guo

University of Pennsylvania

UNITED STATES
View details

Michael Lewis

Baylor College of Medicine

UNITED STATES
View details

Aaron Goldman

Member

The Wistar Institute

UNITED STATES
View details

Qi Long

Professor

University of Pennsylvania

UNITED STATES
View details

Olga Anczukow

Professor

Jackson Laboratory - Farmington

UNITED STATES
View details

Ravi Amaravadi

Associate Professor, Clinician-Educator

University of Pennsylvania

UNITED STATES
View details

Maria Gabriela Raso

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Qin Liu

Professor

The Wistar Institute

UNITED STATES
View details

Soner Koc

GlaxoSmithKline Research and Development

UNITED STATES
View details

Claudia Capparelli

Assistant Professor

Thomas Jefferson University

UNITED STATES
View details

Guanghua Xiao

-

UNITED STATES
View details

Yang Xie

Professor

University of Texas Southwestern Medical Center

UNITED STATES
View details